

Haaaarda

Patient Infor	mation:	<u>паедагаа</u>		
Name:	Mation.			
Member ID:				
Address:				
City, State, Z	· · · · · · · · · · · · · · · · · · ·			
<u>, , , , , , , , , , , , , , , , , , , </u>	•			
Date of Birth:				
Prescriber Ir	nformation:			
Name:				
NPI:				
Phone Numb	er:		-	
Fax Number			-	
Address:			-	
City, State, Z	ip:			
•	• ,			
Requested N	<i>l</i> ledication	т		
Rx Name:				
Rx Strength	<u> </u>			
Rx Quantity:				
Rx Frequency	y:			
Rx Route of	!			
Administration				
Diagnosis an	d ICD Code:			
prescribed a me quantities can b Upon receipt c	edication for your be provided. Plea of the completed	nefit requires that we review certain requests for coverage with the presur patient that requires Prior Authorization before benefit coverage or coverage complete the following questions then fax this form to the toll-free number of form, prescription benefit coverage will be determined based on the toll-free that supporting clinical documentation is required.	verage of number list the plan	f additiona sted below n's rules.
[] He or T	ereditary angioed ype II) (If checked	tion or diagnosis? dema (HAE) prophylaxis due to C1 inhibitor (C1INH) deficiency (Type I ed, go to 2) no further questions)		
	ne patient currer es, skip to ques	ently receiving Haegarda for prophylactic therapy? stion 5.]	Yes	No
(HA	E) (type I or typ	peing provided to show that the patient's hereditary angioedema pe II) has been confirmed by low levels of functional C1-INH 50% of normal) at baseline, as defined by the laboratory	Yes	No

reference values? ACTION REQUIRED: Submit supporting documentation.

	[If no, no further questions.]		
4	Is documentation being provided to show that the patient's hereditary angioedema (HAE) (type I or type II) has been confirmed by lower-than-normal serum C4 levels at baseline, as defined by the laboratory reference values? ACTION REQUIRED: Submit supporting documentation. [If yes, skip to question 7.] [If no, no further questions.]	Yes	No
5	Is documentation being provided to confirm the patient's hereditary angioedema (HAE) (type I or type II) diagnosis? ACTION REQUIRED: Submit supporting documentation. [If no, no further questions.]	Yes	No
6	According to the prescriber, has the patient had a favorable clinical response since initiating Haegarda prophylactic therapy compared with baseline (that is, prior to initiating prophylactic therapy)? [Note: Examples of favorable clinical response include decrease in HAE acute attack frequency, decrease in HAE attack severity, or decrease in duration of HAE attacks.] [If no, no further questions.]	Yes	No
7	Is this medication being prescribed by, or in consultation with, an allergist/immunologist or a physician who specializes in the treatment of Hereditary Angioedema (HAE) or related disorders? [If no, no further questions.]	Yes	No
8	Is this medication being used in combination with other HAE prophylactic therapies (for example, Cinryze, Takhzyro)? [Note: Patients may use other medications, including Cinryze, for treatment of acute HAE attacks, and for short-term (procedural) prophylaxis.]	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE



FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.